Genetic Counselors’ Experience with Cell-Free Fetal DNA Testing as a Prenatal Screening Option for Aneuploidy
- 891 Downloads
First identified in 1997, cell-free fetal DNA (cffDNA) has just recently been used to detect fetal aneuploidy of chromosomes 13, 18, and 21, showing its potential to revolutionize prenatal genetic testing as a non-invasive screening tool. Although this technological advancement is exciting and has certain medical applications, it has been unclear how it will be implemented in a clinical setting. Genetic counselors will likely be instrumental in answering that question, but to date, there is no published research regarding prenatal counselors’ implementation of and experiences with cffDNA testing. We developed a 67 question survey to gather descriptive information from counselors regarding their personal opinions, experiences, thoughts, and concerns regarding the validity, usefulness, and implementation of this new technology. A total of 236 individuals completed a portion of the survey; not all respondents answered all questions. Qualitative questions complemented quantitative survey items, allowing respondents to voice their thoughts directly. Results indicate that counselors value cffDNA testing as a screening option but are concerned regarding how some obstetricians and patients make use of this testing. Further results, discussion, and practice implications are presented.
KeywordsCell-free fetal DNA Non-invasive prenatal testing Genetic counseling Prenatal Screening Aneuploidy
This study was completed in partial fulfillment of the requirements for the first author’s Master of Science degree. The authors would like to thank the respondents for their insightful comments.
Conflict of Interest
Authors Julie M. H. Horsting, Stephen R. Dlouhy, Katelyn Hanson, Kimberly Quaid, Shaochun Bai, and Karrie A. Hines declare they have no conflict of interest.
- Bianchi, D. W., Platt, L. D., Goldberg, J. D., Abuhamad, A. Z., Sehnert, A. J., & Rava, R. P. (2012). Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. MatErnal Blood Is Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Obstetrics and Gynecology, 119, 890–901.PubMedCrossRefGoogle Scholar
- Devers, P. L., Cronister, A., Ormond, K. E., Facio, F., Brasington, C. K., & Flodman, P. (2012). Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the national society of genetic counselors. Journal of Genetic Counseling. doi: 10.1007/s10897-012-9564-0.PubMedGoogle Scholar
- Norton, M. E., Brar, H., Meiss, J., Karimi, A., Laurent, L. C., Caughey, A. B., et al. (2012). Non-Invasive Chromosomal Evaluation (NICE) study: results of a multicenter, prospective, cohort study for detection of fetal trisomy 18. American Journal of Obstetrics and Gynecology, 207(2), 137.e1–137.e8.CrossRefGoogle Scholar
- Palomaki, G. E., Deciu, C., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., et al. (2012). DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genetics in Medicine, 14, 296–305.PubMedCentralPubMedCrossRefGoogle Scholar
- Patton, M. Q. (2001). Qualitative evaluation and research methods. Thousand Oaks: Sage.Google Scholar
- Taylor, J.B., Chock, V.Y., Hudgins, L. (2013). NIPT in a clinical setting: an analysis of uptake in the first months of clinical availability. Journal of Genetic Counseling [Epub ahead of print].Google Scholar
- Vahanian, S.A., Baraa, A.M., Yeh, C., Chavez, M.R., Kinzler, W.L., Vintzileos, A.M. (2013). Patient acceptance of non-invasive testing for fetal aneuploidy via cell-free fetal DNA. Journal of Maternal-Fetal and Neonatal Medicine. PMID: 23687914.Google Scholar